Upsher-Smith Announces Development Agreement With Lundbeck

MAPLE GROVE, Minn., Sept. 30, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, today announced that its UK subsidiary, Proximagen Limited, has entered into a preclinical development agreement with Denmark-based H. Lundbeck A/S (Lundbeck) to further its research program related to protein kinase inhibitors.  This transaction is part of Upsher-Smith's long-term strategy to advance its current product portfolio of branded drugs. Specific terms related to the deal have not been disclosed.

(Logo: )

"Upsher-Smith is pleased to announce today's development agreement with Lundbeck. We are very impressed with the world-class research conducted by Lundbeck and excited about the opportunity to bring a new therapy forward that may benefit patients," said Mark Evenstad, President and Chief Executive Officer of Upsher-Smith.

"Forming successful alliances is a key strategic objective for Lundbeck.  We share Upsher-Smith's commitment to develop therapies that may have the potential to improve the lives of people living with challenging medical conditions," said Ulf Wiinberg, Chief Executive Officer of Lundbeck.

About Upsher-Smith
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases, and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit


SOURCE Upsher-Smith Laboratories, Inc.


More by this Source

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.